Phlow
NEWS
As part of the agreement, Phlow will help build the United States’ first Strategic Active Pharmaceutical Ingredients Reserve, a long-term, national stockpile to secure key ingredients used to manufacture the most essential medicines in the United States.
IN THE PRESS
Phlow Corp., a U.S.-based essential medicines public benefit company, announced strategic alliances with both Virginia Commonwealth University’s Medicines for All Institute and AMPAC Fine Chemicals to provide contract continuous manufacturing research and development services for small molecule pharmaceutical products.
Children’s Hospital Los Angeles joins in announcing the launch of a groundbreaking Children’s Hospital Coalition: Powered by Phlow™.
Phlow Corp., a public benefit essential medicines solutions provider, and the United States Pharmacopeia (USP) today announced a strategic alliance to develop a new laboratory that will certify and validate Pharmaceutical Continuous Manufacturing processes resulting in affordable, high-quality, U.S.-manufactured essential medicines.
Phlow, a U.S.-based, public benefit drug manufacturing corporation, has received federal government funding of $354 million for advanced manufacturing of America’s most essential medicines at risk of shortage, including medicines for the COVID-19 pandemic response.
JOBS